119 related articles for article (PubMed ID: 20680964)
1. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
Subbiah IM; Brown RE; Fallon MB
Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
[No Abstract] [Full Text] [Related]
2. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
3. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
Sharp ZD; Strong R
J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
[No Abstract] [Full Text] [Related]
4. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
5. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Huynh H
Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin: the cure for all that ails.
Hasty P
J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
Soll C; Clavien PA
Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365
[No Abstract] [Full Text] [Related]
9. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S; Thompson JA
Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
[TBL] [Abstract][Full Text] [Related]
11. Pilot study: rapamycin in advanced hepatocellular carcinoma.
Schöniger-Hekele M; Müller C
Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
[TBL] [Abstract][Full Text] [Related]
12. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Decaens T; Duvoux C
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
[TBL] [Abstract][Full Text] [Related]
13. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
Ji J; Zheng PS
Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
[TBL] [Abstract][Full Text] [Related]
14. Functional consequences of mTOR inhibition.
Sudarsanam S; Johnson DE
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
17. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular cancer, transplantation, and sirolimus.
Wall WJ
Liver Transpl; 2004 Oct; 10(10):1312-4. PubMed ID: 15376337
[No Abstract] [Full Text] [Related]
20. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
